Publicado sep 21, 2012



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar


Juan Carlos Ayala Acosta

Juan David Lotero Gómez

##plugins.themes.bootstrap3.article.details##

Resumen

El cáncer gástrico es el cuarto cáncer más frecuente en el mundo y es la segunda causa de mortalidad por cáncer. es más frecuente en países en vía de desarrollo, por lo que su detección temprana y un tratamiento oportuno son estrategias clave para reducir la mortalidad. en esta revisión se expondrán datos recientes, en cuanto a epidemiología y los métodos más eficaces para la tamización del cáncer gástrico, los cuales continúan siendo permanente objeto de revisión y controversia en el mundo, debido a la aparición de nuevas técnicas que permiten identificar con mayor claridad lesiones cancerígenas incipientes o lesiones preneoplásicas. Por lo anterior, en esta revisión de la literatura se busca conocer los métodos de tamización que hoy en día se realizan para la detección temprana del cáncer gástrico y así poder realizar un manejo temprano y oportuno de la enfermedad.

Keywords

cáncer gástrico, tamizaje, mortalidad, prevalencia, Gastric cancer, screening, mortality, prevalence,

References
1. instituto nacional de Cancerología. Protocolos en el manejo de pacientes con cáncer. Bogotá; s. f.
2. World Health Organization. Cancer [internet]. disponible en: http://www.who.int/topics/cancer/en/index.html.
3. World Health Organization. Early detection of cancer [internet]. disponible en: http://www.who.int/cancer/detection/en/index.html.
4. Bogatyrev VN, Gueddana N, Miller A et al. Control del cáncer: aplicación de los conocimientos: módulo 3. Washington: OMs; 2007.
5. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2008: fast stats [internet]. disponible en: http://globocan.iarc.fr/factsheet.asp.
6. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2008. Fast stats: summary statistics [internet]. disponible en: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#KeY.
7. instituto nacional de Cancerología. Tablas por tipo de cáncer y sexo: incidencia estimada por cáncer, según localización y sexo, 2002-2006 [internet]. disponible en: http://www.cancer.gov.co/contenido/contenido.aspx?catid=437&conid=790&pagid=1303.
8. Crew Kd, neugut Ai. epidemiology of gastric cancer. World J Gastroenterol. 2006 Jan 21;12(3):354-62.
9. El-Serag HB, Mason AC, Petersen n, Key CR. epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the UsA. Gut. 2002 Mar;50(3):368-72.
10. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1992 Apr;1(3):265-9.
11. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer Clin J. 2002;52:23-47.
12. Catalano V, Labianca R, Beretta GD, Gatta G, Braud F, Van Custem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127-64.
13. verdecchia A, Corazziari i, Gatta G, Lisi D, Faivre J, Forman D. Explaining gastric cancer survival differences among European countries. Int J Cancer. 2004;109:737-41.
14. Clark CJ, Thirlby RC, Picozzi Jr. V, Schembre DB, Cummings FP, Lin E. current problems in surgery: gastric cancer. Curr Probl surg. 2006;43(8-9):566-670.
15. Shang J, Pena AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol. 2005;11:4131-9.
16. Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer – aetiology and pathogenesis. Best Prac Res Clin Gastroenterol. 2009;23(2):147-57.
17. Guilford PJ, Hopkins JB, Grady WM et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14(3):249-55.
18. Pharoah Pd, Guilford P, Caldas C; international Gastric Cancer Linkage Consortium. incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001 dec; 121(6):1348-53.
19. Caldas C, Carneiro F, Lynch HT et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36(12):873-80.
20. Masciari s, dewanwala A, stoffel eM et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Gen Med. 2011 Jul;13(7):651-7.
21. Kolonel LN, Nomura AM, Hirohata T, Hankin JH, Hinds MW. Association of diet and place of birth with stomach cancer incidence in Hawaii Japanese and Caucasians. Am J Clin Nutr. 1981 nov;34(11):2478-85.
22. WCRF & AiCR. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, dC: AiCR; 2007.
23. World Health Organization. Diet, Nutrition, and the prevention of chronic diseases: report of a joint WHO/FAO Expert Consultation. Geneva: WHO; 2003.
24. iARC Working Group on the evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7-14 June 1994. IARC, Monogr Eval Carcinog Risks Hum 1994;61:1-241.
25. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169-79.
26. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9 suppl 2:45-51.
27. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001 sep;49(3):347-53.
28. Yamaguchi n, Kakizoe T. synergistic interaction between Helicobacter pylori gastritis and diet in gastric cancer. Lancet Oncology. 2001 Feb;2(2):88-94.
29. Gonzalez CA, Pera G, Agudo A et al. smoking and the risk of gastric cancer in the european prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2003;107:629-34.
30. Chao A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle ee. Cigarette smoking, use of other tobacco products and stomach cancer mortality in Us adults: The Cancer Prevention study ii. Int J Cancer. 2002;101:380-9.
31. sjodahl K, Lu Y, nilsen Ti et al. smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. Int J Cancer. 2007;120:128-32.
32. Rokkas T, Filipe Mi, sladen Ge. detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type iii who are closely followed up. Gut. 1991;32:1110-3.
33. Leung WK, Sung JJ. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther. 2002;16:1209-16.
34. Borch K, Skarsgård J, Franzén L, Mårdh s, Rehfeld JF. Benign gastric polyps: morphological and functional origin. dig dis sci. 2003;48(7):1292-7.
35. Cristallini E, Ascani S, Bolis G. Association between histologic type of polyp and carcinoma in the stomach. Gastrointest endosc. 1992;38:481-4.
36. Orlowska J, Jarosz D, Pachlewski J, Butruk E. Malignant transformation of benign epithelial gastric polyps. Am J Gastroenterol. 1995;90:2152-9.
37. dubrow R. Gastric cancer following peptic ulcer surgery. J Natl Cancer Inst. 1993 Aug 18;85(16):1268-70.
38. Northfield TC, Hall CN. Carcinoma of the gastric stump: risk and pathogenesis. Gut. 1990 nov;31(11):1217-9.
39. Zhang Z. The risk of gastric cancer in patients with duodenal and gastric ulcer: research progresses and clinical implications. J Gastroint Cancer. 2007;38(1):38-45.
40. Cho SJ, Choi IJ, Kim CG, Kook MC et al. Risk factors associated with gastric cancer in patients with duodenal ulcer. Helicobacter. 2010 dec;15(6):516-23.
41. Leung WK, Wu Ms, Kakugawa Y et al; Asia Pacific Working Group on Gastric Cancer. screening for gastric cancer in Asia: current evidence and practice. Lancet Oncology. 2008 Mar;9(3):279-87.
42. Tsukuma H, Oshima A, Narahara H, Morii T. natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut. 2000 nov; 47(5):618-21.
43. inoue M, Tsugane s. epidemiology of gastric cancer in Japan. Postgrad Med J. 2005 Jul;81(957):419-24.
44. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245-53.
45. shiotani A, Iishi H, Uedo n et al. Histologic and serum risk markers for noncardia early gastric cancer. International J Cancer. 2005 Jun 20;115(3):463-9.
46. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ et al; nCCn Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc netw. 2010 Apr;8(4):378-409.
47. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach and colon. Gastroint endosc. 2003 dec; 58(6 suppl):s3-43.
48. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroent Hepatol. 2006;4:709-16.
49. Parsonnet J, Harris RA, Hack HM, Owens dK. Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150-4.
50. Roderick P, Davies R, Raftery J et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen. 2003;10:148-56.
Cómo citar
Ayala Acosta, J. C., & Lotero Gómez, J. D. (2012). Tamización de cáncer gástrico. Universitas Medica, 54(2), 209–222. https://doi.org/10.11144/Javeriana.umed54-2.tcga
Sección
Artículos de revisión